BioSpace News Archive

Matinas BioPharma Holdings, Inc. announces that James J. Ferguson, M.D., Chief Medical Officer of Matinas, will be presenting two abstracts at the ASGCT 27th Annual Meeting being held May 7-11, 2024 in Baltimore highlighting data from ex vivo, in vitro and in vivo studies evaluating the use of Matinas’ LNC platform for the uptake and targeted delivery of small oligonucleotides.

MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, announced its financial results for the first quarter of 2024.

Alimera Sciences, Inc. announced it will have three scientific abstracts at two upcoming ophthalmic congresses including the Association for Research in Vision and Ophthalmology conference, scheduled in Seattle, WA. from May 5 - 9 and Retina World Congress scheduled in Fort Lauderdale, FL. from May 9 - 13.

Sirona Biochem Corp. has announced a partnership with Stonegate Healthcare Partners. Stonegate is a leading corporate advisory firm based in Dallas, Texas that offers research driven business development and investor outreach services.

Integer Holdings Corporation will join medtech industry leaders around the world in exhibiting at Heart Rhythm 2024, a Heart Rhythm Society educational event and exhibition in Boston from May 16 – 19, 2024.

Traws Pharma, Inc. announced that it completed dosing in the first cohort of the first-in-human Phase 1 study to evaluate travatrelvir, an orally-available protease inhibitor, in development for treatment of COVID19.

Biora Therapeutics, Inc., the biotech company that is reimagining therapeutic delivery, announced it will report financial results and provide a corporate update for the first quarter ended March 31, 2024.

Oragenics, Inc., a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, announced a partnership with Avance Clinical, a leading Contract Research Organization, to conduct a Phase II clinical trial in Australia.

4D Molecular Therapeutics, a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, announced that management will participate in a fireside chat at an upcoming investor conference in May.

Windtree Therapeutics, Inc. announced it has received a Bid Price Compliance Letter from The Nasdaq Stock Market LLC informing Windtree that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.